Karmanos Researchers Identify Pathway for Treatment of Malignant Pleural Mesothelioma
Source: Barbara Ann Karmanos Cancer Institute
Scientists from the Barbara Ann Karmanos Cancer Institute, one of the major cancer research centers in the United States, announced significant results in their latest research into the treatment of malignant pleural mesothelioma. Karmanos researches studying the ubiquitin-proteasome proteolytic (UPP) pathway determined that protein ubiquitination and degradation are essential elements in the progression of mesothelioma. 33 of the 241 genes involved in the UPP pathway are differentially expressed among epithelioid and biphasic mesothelioma [two of the three mesothelioma sub-types]. These findings prompted Anil Wali, a Ph.D. and the Karmanos assistant professor who led th study, to conclude that "...if we can develop a therapy to target this pathway, we will be one step closer to halting this disease."
The results of the Karmanos research were presented at the American Association for Cancer Research (AACR) annual meeting in Los Angeles, CA. Funding for the study was provided by the Environmental Protection Agency (EPA) and the Center for Disease Control (CDC).
More information on the ubiquitin-proteasome proteolytic (UPP) pathway can be found at the Wikipedia entry for proteasomes.
Scientists from the Barbara Ann Karmanos Cancer Institute, one of the major cancer research centers in the United States, announced significant results in their latest research into the treatment of malignant pleural mesothelioma. Karmanos researches studying the ubiquitin-proteasome proteolytic (UPP) pathway determined that protein ubiquitination and degradation are essential elements in the progression of mesothelioma. 33 of the 241 genes involved in the UPP pathway are differentially expressed among epithelioid and biphasic mesothelioma [two of the three mesothelioma sub-types]. These findings prompted Anil Wali, a Ph.D. and the Karmanos assistant professor who led th study, to conclude that "...if we can develop a therapy to target this pathway, we will be one step closer to halting this disease."
The results of the Karmanos research were presented at the American Association for Cancer Research (AACR) annual meeting in Los Angeles, CA. Funding for the study was provided by the Environmental Protection Agency (EPA) and the Center for Disease Control (CDC).
More information on the ubiquitin-proteasome proteolytic (UPP) pathway can be found at the Wikipedia entry for proteasomes.
Labels: mesothelioma
posted by Belluck & Fox at
2:44 PM
© Belluck & Fox, L.L.P. All rights reserved.
